|
注册号: Registration number: |
ChiCTR2400094344 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-27 18:12:34 |
|
注册时间: Date of Registration: |
2024-12-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
老年冠心病患者参与用药安全管理的药学服务模式构建与评价研究 |
|
Public title: |
Pharmaceutical Service Model Construction and Evaluation for Elderly Coronary Heart Disease Patients' Participation in Medication Safety Management |
|
注册题目简写: |
老年冠心病患者参与用药安全管理的药学服务模式 |
|
English Acronym: |
Pharmaceutical Service Model for Elderly Coronary Heart Disease Patients' Participation in Medication Safety Management |
|
研究课题的正式科学名称: |
老年冠心病患者参与用药安全管理的药学服务模式构建与评价研究 |
|
Scientific title: |
Pharmaceutical Service Model Construction and Evaluation for Elderly Coronary Heart Disease Patients' Participation in Medication Safety Management |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
谢清 |
研究负责人: |
刘桦 |
|
Applicant: |
Xie Qing |
Study leader: |
Liu Hua |
|
申请注册联系人电话: Applicant telephone: |
+86 152 1008 1662 |
研究负责人电话:
Study leader's |
+86 138 1098 5170 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lcyx721@126.com |
研究负责人电子邮件: Study leader's E-mail: |
lcyx721@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区玉泉路15号 |
研究负责人通讯地址: |
北京市海淀区玉泉路15号 |
|
Applicant address: |
No. 15, Yuquan Road, Haidian District, Beijing |
Study leader's address: |
No. 15, Yuquan Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
航天中心医院 |
||
|
Applicant's institution: |
Aerospace Center Hospital |
||
|
研究负责人所在单位: |
航天中心医院 |
||
|
Affiliation of the Leader: |
Aerospace Center Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
京航医伦审2024第(014)号; 京航医伦审2024第(014-01)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
航天中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Aerospace Center Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-22 00:00:00 | ||
|
伦理委员会联系人: |
时瀚 |
||
|
Contact Name of the ethic committee: |
Shi Han |
||
|
伦理委员会联系地址: |
北京市海淀区玉泉路15号 |
||
|
Contact Address of the ethic committee: |
No. 15, Yuquan Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5997 2383 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
航天中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Aerospace Center Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区玉泉路15号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 15, Yuquan Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
首都卫生发展科研专项项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Capital’s Funds for Health Improvement and Research |
||||||||||||||||||||||
|
研究疾病: |
冠心病 |
||||||||||||||||||||||
|
Target disease: |
Coronary Heart Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
本研究拟通过社区冠心病患者基线调研、问卷调查和现状分析,探索在社区卫生服务站构建基于“药师工作室”的老年冠心病患者参与用药安全管理(PS-PE-MSM)的药学服务模式并进行效果评价。本研究在前期住院患者医疗过渡期药学服务研究的基础上,开展PS-PE-MSM药学服务新模式的研究,打通患者安全用药的最后一公里,实现药学服务下沉。提高患者用药依从性,减少社区老年冠心病患者药物治疗相关问题。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study intends to explore and evaluate the effectiveness of a pharmaceutical service model based on a "Pharmacist Studio" for elderly patients with coronary heart disease (CHD) to participate in medication safety management (PS-PE-MSM) in community health service stations, through baseline surveys, questionnaires, and current situation analyses of community CHD patients. Building on previous research on pharmaceutical services during the medical transition period for hospitalized patients, this study aims to develop the new PS-PE-MSM pharmaceutical service model. It seeks to bridge the final gap in patients' safe medication use, bring pharmaceutical services closer to the community, enhance patients' medication adherence, and reduce medication-related issues for elderly CHD patients in the community. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
第一部分 基线调研 排除标准: ①有智力障碍(Mini-cog评分<3分); ②不签署知情同意书 第三部分 PS-PE-MSM模式的实施与效果评价 排除标准: ①有智力障碍 (Mini-cog评分<3分)、生活能力差(ADL量表评分<40分); 确诊恶性肿瘤患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Part 1 Baseline Survey Exclusion Criteria: Intellectual Impairment: Mini-cog score <3. Non-consent: Refusal to sign the informed consent form. Part 3 Implementation and Effect Evaluation of PS-PE-MSM Model Exclusion Criteria: Impairments: Mini-cog score <3 or ADL score <40. Malignancy: Diagnosed with malignant tumors. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-12-30 00:00:00 至 To 2026-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
整群随机,SPSS软件进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The whole group was randomly grouped by SPSS software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放研究 |
|
Blinding: |
open |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |